AI Article Synopsis

  • - Tadalafil, typically used for benign prostatic hyperplasia (BPH), may also lower the risk of Type 2 diabetes mellitus (T2DM) in patients without prior diabetes.
  • - A study compared 5,180 men who used tadalafil to 20,049 men who used alpha-blockers, finding that tadalafil users had a significantly lower incidence of T2DM over a median follow-up of about 27 months.
  • - The results suggest that tadalafil is associated with a 53% reduction in the risk of developing T2DM compared to alpha-blockers, indicating it might be a better option for preventing diabetes in BPH patients.

Article Abstract

Background: Tadalafil, commonly prescribed for benign prostatic hyperplasia (BPH), may benefit patients with Type 2 diabetes mellitus (T2DM) for glycemic markers and complications. However, the association between the long-term use of tadalafil and the incidence of T2DM has not been investigated.

Methods: We emulated a target trial of tadalafil use (5 mg/day) and the risk of T2DM using a population-based claims database in Japan. Patients who initiated tadalafil or alpha-blockers for BPH and had no history of diabetes diagnosis, no dispensing of glucose-lowering drugs, and no history of hemoglobin A1c levels of ≥6.5% (47-48 mmol/mol) were included. The primary outcome was the incidence of T2DM. Pooled logistic regression was used to estimate adjusted risk ratios (RRs) and 5-year cumulative incidence differences (CIDs).

Results: A total of 5180 participants initiated tadalafil treatment and were compared with 20,049 patients who initiated alpha-blockers. The median follow-up time for each arm was 27.2 months (interquartile range [IQR], 12.0-47.9) in tadalafil users and 31.3 months (IQR, 13.7-57.2) in alpha-blocker users. The incidence rates of T2DM in tadalafil and alpha-blocker users were 5.4 (95% confidence interval [CI], 4.0-7.2) and 8.8 (95% CI, 7.8-9.8) per 1000-person years, respectively. Initiation of tadalafil was associated with a reduced risk of T2DM (RR, 0.47; 95% CI, 0.39-0.62; 5-year CID, -0.031; 95% CI, -0.040 to -0.019).

Conclusion: The incidence of T2DM was lower in men with BPH treated with tadalafil than in those treated with alpha-blockers. Thus, tadalafil may be more beneficial than alpha-blockers in preventing T2DM.

Download full-text PDF

Source
http://dx.doi.org/10.1111/joim.20012DOI Listing

Publication Analysis

Top Keywords

incidence t2dm
12
tadalafil
11
tadalafil associated
8
type diabetes
8
benign prostatic
8
prostatic hyperplasia
8
t2dm
8
risk t2dm
8
patients initiated
8
initiated tadalafil
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!